The next wave of growth will belong not to the fastest manufacturers but to the most innovative problem-solvers Read more
Sun Pharma’s phase 3 clinical studies evaluating ILUMYA in active psoriatic arthritis met their primary endpoint Read more
Lilly’s orforglipron and other key catalysts can reshape drug landscape in Q3 2025: GlobalData Read more